category,datetime,headline,id,image,related,source,summary,url
company,1768505592,Genmab A/S (GMAB): A Bull Case Theory,138126653,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,"We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Genmab is a leading biotechnology company focused […]",https://finnhub.io/api/news?id=a365fccc8221365d68d13fbc31a1899e47faacf1bd644526f0acee2810735645
company,1768495260,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,138212218,,REGN,MarketWatch,Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors,https://finnhub.io/api/news?id=a73f26ec809d4e93c8a68267836a831e0859c1b3e6c69729b1e40341c53a2818
company,1768492587,JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death,138122855,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,REGN,Yahoo,Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare Conference 2026.,https://finnhub.io/api/news?id=05d144e8b97a7e888d85a95eac6199093ab4e8c2a41a65f746717a4a86351e10
company,1768464000,Longleaf Partners Fund 2025 Contributors And Detractors,138120249,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/691574517/image_691574517.jpg?io=getty-c-w1536,REGN,SeekingAlpha,"While 2025 was an underwhelming year for the Fund, there was a clear theme that we can live with in the short term: we did not have enough big winners. Read more here.",https://finnhub.io/api/news?id=8c17eafbf21c2543e93ca2cafc0f6537b81d8a3f6274d856b3326b595ed9faef
